Dr. Emily I. Chen is a highly accomplished scientist with a strong background in molecular pathology and translational medicine. She earned her Ph.D. in Molecular Pathology from the University of California San Diego in 2002, and later received post-doctoral training at the Scripps Research Institute, where she specialized in studies of proteomics alterations in cancer and mechanisms of breast cancer metastasis. After completing her Ph.D., Dr. Chen joined as a principal investigator at Stony Brook University’s Department of Pharmacological Science, and later as the Director of the Proteomics Shared Resource at Columbia University Medical Center, where she led a team in the development and implementation of cutting-edge proteomic technologies for translational research. Her work at Columbia resulted in numerous publications and presentations at national and international conferences. In 2018, Dr. Chen joined Thermo Fisher Scientific as the Senior Director of the Precision Medicine Science Center. In this role, she oversaw a team of scientists who worked with academics and pharmaceutical businesses to create precision medicine technologies such as next-generation sequencing and companion diagnostic biomarker analysis. Throughout her career, Dr. Chen has been involved in numerous research initiatives and collaborations, resulting in over 60 publications in peer-reviewed journals. She is also a frequent conference speaker and has been recognized for her contributions to proteomics and translational research. Dr. Chen's expertise and leadership have made her a highly sought-after consultant and advisor for biotechnology and pharmaceutical companies. She continues to be a driving force in the advancement of precision medicine, with a focus on improving patient outcomes and revolutionizing healthcare.